Tubulointerstitial fibrosis (TIF) is the final common pathway in the end-stage renal disease. Epithelial-to-mesenchymal transition (EMT) is considered a major contributor to the TIF by increasing the number of myofibroblasts. Curcumin, a polyphenolic compound derived from rhizomes of Curcuma, has been shown to possess potent anti-fibrotic properties but the mechanism remains elusive. We found that curcumin inhibited the EMT as assessed by reduced expression of α-SMA and PAI-1, and increased E-cadherin in TGF-β1 treated proximal tubular epithelial cell HK-2 cells. Both of the conventional TGF-β1/Smad pathway and non-Smad pathway were investigated. Curcumin reduced TGF-β receptor type I (TβR-I) and TGF-β receptor type II (TβR II), but had no effect on phosphorylation of Smad2 and Smad3. On the other hand, in non-Smad pathway curcumin reduced TGF-β1-induced ERK phosphorylation and PPARγ phosphorylation, and promoted nuclear translocation of PPARγ. Further, the effect of curcumin on α-SMA, PAI-1, E-cadherin, TβR I and TβR II were reversed by ERK inhibitor U0126 or PPARγ inhibitor BADGE, or PPARγ shRNA. Blocking PPARγ signaling pathway by inhibitor BADGE or shRNA had no effect on the phosphorylation of ERK whereas the suppression of ERK signaling pathway inhibited the phosphorylation of PPARγ. We conclude that curcumin counteracted TGF-β1-induced EMT in renal tubular epithelial cells via ERK-dependent and then PPARγ-dependent pathway.
References
[1]
Zeisberg M, Kalluri R (2004) The role of epithelial-to-mesenchymal transition in renal fibrosis. Journal of Molecular Medicine 82: 175–181.
[2]
Yang J, Liu Y (2001) Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. The American Journal of Pathology 159: 1465–1475.
[3]
Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425: 577–584.
[4]
Miyazono K, Ten Dijke P, Heldin CH (2000) TGF-β signaling by Smad proteins. Advances in immunology 75: 115–157.
[5]
Moustakas A, Heldin CH (2005) Non-Smad TGF-β signals. Journal of Cell Science 118: 3573–3584.
[6]
Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, et al. (2008) PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β. Laboratory Investigation 89: 47–58.
[7]
Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annual review of medicine 53: 409–435.
[8]
Yang J, Zhang D, Li J, Zhang X, Fan F, et al. (2009) Role of PPARγ in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential. Clinical Science 116: 17.
[9]
Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB (2001) Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney International 59: 1899–1910.
[10]
Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, et al. (2002) Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Molecular and Cellular Biology 22: 2607–2619.
[11]
Han JY, Kim YJ, Kim L, Choi SJ, Park IS, et al. (2010) PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis. Journal of Korean medical science 25: 35.
[12]
Maheshwari RK, Singh AK, Gaddipati J, Srimal RC (2006) Multiple biological activities of curcumin: a short review. Life Sciences 78: 2081–2087.
[13]
Yao Q, Xu B, Wang J, Liu H, Zhang S, et al. (2012) Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. BMC Complementary and Alternative Medicine 12: 156.
[14]
Punithavathi D, Venkatesan N, Babu M (2009) Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. British Journal of Pharmacology 131: 169–172.
[15]
Lipecka J, Norez C, Bensalem N, Baudouin-Legros M, Planelles G, et al. (2006) Rescue of ΔF508-CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) by Curcumin: Involvement of the Keratin 18 Network. Journal of Pharmacology and Experimental Therapeutics 317: 500–505.
[16]
Kuwabara N, Tamada S, Iwai T, Teramoto K, Kaneda N, et al. (2006) Attenuation of renal fibrosis by curcumin in rat obstructive nephropathy. Urology 67: 440–446.
[17]
Gaedeke J, Noble NA, Border WA (2004) Curcumin blocks multiple sites of the TGF-b signaling cascade in renal cells. Kidney International 66: 112–120.
[18]
Chen A, Xu J (2005) Activation of PPARγ by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. American Journal of Physiology-Gastrointestinal and Liver Physiology 288: G447–G456.
[19]
Narala VR, Smith MR, Adapala RK, Ranga R, Panati K, et al. (2009) Curcumin is not a ligand for peroxisome proliferator-activated receptor-gamma. Gene Ther Mol Biol 13: 20–25.
[20]
Wu MY, Hill CS (2009) TGF-β Superfamily Signaling in Embryonic Development and Homeostasis. Developmental Cell 16: 329–343.
[21]
Wang W, Koka V, Lan HY (2005) Transforming growth factor-β and Smad signalling in kidney diseases. Nephrology 10: 48–56.
[22]
Yan X, Liu Z, Chen Y (2009) Regulation of TGF-β signaling by Smad7. Acta Biochimica et Biophysica Sinica 41: 263–272.
[23]
Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. Journal of Clinical Investigation 112: 1776–1784.
[24]
Zavadil J, B？ttinger EP (2005) TGF-β and epithelial-to-mesenchymal transitions. Oncogene 24: 5764–5774.
[25]
Willis BC, Borok Z (2007) TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. American Journal of Physiology-Lung Cellular and Molecular Physiology 293: L525–L534.
[26]
Ghosh AK, Vaughan DE (2012) PAI-1 in tissue fibrosis. Journal of Cellular Physiology 227: 493–507.
[27]
Hu Y, Liang H, Du Y, Zhu Y, Wang X (2010) Curcumin Inhibits Transforming Growth Factor-β Activity via Inhibition of Smad Signaling in HK-2 Cells. American Journal of Nephrology 31: 332–341.
[28]
Rojas A, Padidam M, Cress D, Grady WM (2009) TGF-[beta] receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-[beta]. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1793: 1165–1173.
[29]
Li Y, Chen Z, Li Y (2011) Effects of curcumin on the epithelial mesenchymal transition and TGF-beta/Smads signaling pathway in unilateral ureteral obstruction rats. Zhongguo Zhong yi yan jiu yuan zhu ban 31: 1224.
[30]
Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, et al. (2004) Activation of the Erk pathway is required for TGF-β1-induced EMT in vitro. Neoplasia (New York, NY) 6: 603.
[31]
Xie L, Law BK, Aakre ME, Edgerton M, Shyr Y, et al. (2003) Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res 5: R187–R198.
[32]
Abbott BD (2009) Review of the expression of peroxisome proliferator-activated receptors alpha (PPARα), beta (PPARβ), and gamma (PPARγ) in rodent and human development. Reproductive Toxicology 27: 246–257.
[33]
Kiss-Tóth é, R？szer T (2008) PPARγ in Kidney Physiology and Pathophysiology. PPAR Research 2008: 183108.
[34]
Panchapakesan U, Sumual S, Pollock CA, Chen X (2005) PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. American Journal of Physiology-Renal Physiology 289: F1153–F1158.
[35]
Ko GJ, Kang YS, Han SY, Lee MH, Song HK, et al. (2008) Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrology Dialysis Transplantation 23: 2750–2760.
[36]
Chung B, Lim S, Ahn K, Sugawara A, Ito S, et al. (2005) Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrology 10: S40–S43.
[37]
Chen A, Zheng S (2009) Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-κB and ERK signalling. British Journal of Pharmacology 153: 557–567.
[38]
Ghosh SS, Massey HD, Krieg R, Fazelbhoy ZA, Ghosh S, et al. (2009) Curcumin ameliorates renal ailure in 5/6 nephrectomized rats: role of inflammation. American Journal of Physiology-Renal Physiology 296: F1146–F1157.
[39]
Gao J, Zhou H, Lei T, Zhou L, Li W, et al. (2011) Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. European journal of pharmacology 654: 92–99.
[40]
Diradourian C, Girard J, Pégorier JP (2005) Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 87: 33–38.
[41]
Rochette-Egly C (2003) Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cellular Signalling 15: 355–366.
[42]
Burgermeister E, Seger R (2008) PPARγ and MEK Interactions in Cancer. PPAR Research 2008: 1–16.
